But the coronavirus pandemic continues to create uncertainty for the medical device maker.
News & Analysis: Edwards Lifesciences
EW earnings call for the period ending June 30, 2020.
The two companies' agreement puts to rest an escalating dispute over heart valve repair products.
Strong revenue growth and low debt make this stock a winner.
Positive trial results, sales growth, and general market gains led the shares higher.
The COVID-19 outbreak took a heavy toll on the company's sales at the end of Q1. And the problems will likely get worse before they get better.
EW earnings call for the period ending March 31, 2020.
These companies -- a medical device maker and a consumer goods player -- have what it takes to offer long-term revenue growth.
Let's dig into what investors should think of this healthcare giant in the current bear market.
The medical device maker expects a strong 2020 performance with growing demand for its artificial heart valve products.